In breast tumor derived cell lines with different phenotypes we previously found that the level of CD133 inversely correlates with PLC-β2 and that over-expression of this PLC isozyme in MDA-MB-231 cells down-modulates CD133 at both membrane and intracellular levels [17]. The gene discussed is HSPG2; the disease is breast neoplasm.